AN2 Therapeutics, Inc. (ANTX) Insider Trading -- Recent Executive & Director Transactions

12 insiders reported 45 Form 4 transactions for AN2 Therapeutics, Inc. (ANTX) over the past 18 months (most recent 2026-06-02). Recent activity: Williams Sarah Joanne (Principal Accounting Officer) Sell 265 shares, Aziz Kabeer (Director) Buy 3,775 shares, Martin Patricia A. (Director) Buy 1,192 shares, Marks Gilbert Lynn (Director) Buy 3,775 shares, Williams Sarah Joanne (Principal Accounting Officer) Sell 327 shares. Source: SEC Form 4.

DateInsiderTitleTypeSharesValue
2026-06-02Williams Sarah JoannePrincipal Accounting OfficerSell265$1,174
2026-04-10Aziz KabeerDirectorBuy3,775$0
2026-04-10Martin Patricia A.DirectorBuy1,192$0
2026-04-10Marks Gilbert LynnDirectorBuy3,775$0
2026-03-05Williams Sarah JoannePrincipal Accounting OfficerSell327$347
2026-02-23Chanda SanjayChief Development OfficerBuy38,000$0
2026-02-23Day LucyChief Financial OfficerBuy38,000$0
2026-02-23Williams Sarah JoannePrincipal Accounting OfficerBuy48,375$0
2026-02-23Easom EricChief Executive OfficerBuy112,250$0
2026-02-23Eizen Joshua MSee RemarksBuy50,000$0
2026-01-14Marks Gilbert LynnDirectorBuy11,560$0
2026-01-14Aziz KabeerDirectorBuy11,560$0
2026-01-14Martin Patricia A.DirectorBuy3,650$0
2026-01-07Day LucyChief Financial OfficerSell3,295$3,295
2026-01-07Day LucyChief Financial OfficerSell5,512$5,567
2026-01-07Eizen Joshua MSee RemarksSell17,923$17,923
2026-01-07Eizen Joshua MSee RemarksSell6,931$7,000
2026-01-07Prior Stephen DavidChief Strategy OfficerSell3,604$3,604
2026-01-07Prior Stephen DavidChief Strategy OfficerSell2,858$2,887
2026-01-07Chanda SanjayChief Development OfficerSell3,295$3,295
2026-01-07Chanda SanjayChief Development OfficerSell5,956$6,016
2025-11-06Prior Stephen DavidChief Strategy OfficerSell765$872
2025-11-06Eizen Joshua MSee RemarksSell2,819$3,214
2025-10-14Marks Gilbert LynnDirectorBuy10,367$0
2025-10-14Aziz KabeerDirectorBuy10,367$0

Source: SEC Form 4 filings · as of 2026-06-02